Displaying drugs 11251 - 11275 of 11462 in total
Luveltamab tazevibulin
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
Matched Description: … [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate …
CMLVAX100
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Investigational
Matched Description: … CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease …
HGTV-43
HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.
Investigational
Matched Description: … HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company …
Foretinib
Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits...
Investigational
INCB13739
INCB13739 is developed as a new treatment for type 2 diabetes.
It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes.
Investigational
Matched Description: … INCB13739 is developed as a new treatment for type 2 diabetes. …
CYT007-TNFQb
CYT007-TNFQb is an active immunization therapy that aims at
providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low
amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.
Investigational
Matched Description: … CYT007-TNFQb is an active immunization therapy that aims at
providing a novel treatment to people suffering …
N-(carboxycarbonyl)-D-phenylalanine
N-(carboxycarbonyl)-D-phenylalanine is a solid. This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. It targets the protein hypoxia-inducible factor 1-alpha inhibitor.
Experimental
Matched Description: … N-(carboxycarbonyl)-D-phenylalanine is a solid. …
Cetrelimab
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
Investigational
Matched Description: … Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics …
CSL324
CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.
Investigational
Matched Description: … CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia …
SynOV1.1
SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).
Investigational
Matched Description: … It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating …
Gabexate
Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]
Investigational
Matched Description: … Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. …
Serrapeptase
Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular infections. Serratiopeptidase is under investigation in clinical trial NCT02493179 (Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery).
Investigational
Matched Description: … Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular …
Pinatuzumab vedotin
Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)).
Investigational
Matched Description: … Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin …
R673
R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential. The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but...
Investigational
Matched Description: … R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability …
13-deoxydoxorubicin
GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.
Investigational
Fradafiban
Investigational
SO-101
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected …
Liposomal prostaglandin E1
Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve.
Investigational
Matched Description: … Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet …
TD-2749
TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
Investigational
Matched Description: … selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a …
R-348
Investigational
Nicotinamide Mononucleotide
3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5'phosphate, inner salt. A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN. [PubChem]
Experimental
Matched Description: … A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C- …
BF-37
BF-37 for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis.
Investigational
Matched Description: … The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct …
SB-269970
SB-269970 is an experimental drug developed by GlaxoSmithKline. In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817]
Investigational
Matched Description: … In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective …
(S)-Warfarin
Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways. S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.
Experimental
Investigational
Matched Description: … Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared …
Hu-rhEGF-rP64k/Mont
Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated for the treatment of advanced non-small cell lung cancer (NSCLC).
Investigational
Matched Description: … Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically …
Displaying drugs 11251 - 11275 of 11462 in total